Author: Willem van Lawick

On April 7th, 2010 the first iVAC3L case was carried out in Sheba Medical Center, Tel Aviv, Israel, by Dr. Yigal Cassif. The patient was a 53yr old male who was suffering from acute myocarditis with cardiogenic shock after resuscitation with IABP and required emergency support. Before implantation of the iVAC3L he had an EF of… Continue reading First iVAC3L Case in Israel

Leiden, March 30, 2010 – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics announces the start of a phase I/II clinical study for PRO044 in patients with Duchenne Muscular Dystrophy. The objective of this open label, dose-escalating study is to evaluate the safety and tolerability of the systemic delivery of PRO044 in… Continue reading Prosensa initiates clinical development of PRO044 in an open label phase I/II study – Prosensa’s second clinical candidate for treatment of Duchenne Muscular Dystrophy

Leiden, March 17, 2010 – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, announces the appointment of Berndt Modig as Chief Financial Officer (CFO).

Dutch-based donor organ perfusion devices companyOrgan Assist BV today announced the successful completion of second round investment led by Dutch investor MedSciences Capital BV from Amsterdam, The Netherlands. Also participating in this equity investment are De Friesland Zorgverzekeraar NV, Hanzepoort BV, NoordTechVenture BV, Kennisconversiefonds BV and G.J. Smidfonds BV, all from the Netherlands. The financing… Continue reading Brake through to decrease the waiting list of organ transplantation

On February 3rd the first iVAC 3L case was carried out in Erasme ULB hospital, Belgium, by Dr Frederic Vandeneynden. The patient was a 65yr old female who had been transferred to the ICU after bypass surgery and who had been unable to recover. Before implantation of the iVAC 3L she had a CO of 2.9L/M,… Continue reading First iVAC 3L Case in Belgium